Immune Thrombocytopenia Medical Services in China

Immune Thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder characterized by isolated low platelet counts (thrombocytopenia) — typically <100 × 10⁹/L — in the absence of other causes such as malignancy, infection, or drug exposure. In ITP, the immune system mistakenly produces autoantibodies (most commonly IgG targeting glycoprotein IIb/IIIa or Ib/IX on platelet surfaces), leading to premature platelet destruction by Fc receptor–bearing macrophages in the spleen and impaired megakaryocyte maturation in the bone marrow. This dual mechanism — peripheral destruction and central production failure — underpins the pathophysiology. Primary ITP is idiopathic; secondary forms may accompany systemic lupus erythematosus, chronic lymphocytic leukemia, HIV, or H. pylori infection. Epidemiologically, ITP has a bimodal incidence: children (often post-viral, acute, self-limiting) peak at ages 2–6 years, while adults show a steady rise after age 40, with female predominance (F:M ≈ 2–3:1). The overall incidence is approximately 3.3 per 100,000 person-years in adults and 5.3 per 100,000 in children; prevalence in adults is estimated at 9–10 per 100,000. Key risk factors include female sex, age >60 years, autoimmune comorbidities (e.g., thyroid disease, rheumatoid arthritis), and certain infections (e.g., H. pylori, hepatitis C, HIV). While many patients are asymptomatic, clinical manifestations range from mild mucocutaneous bleeding (petechiae, purpura, epistaxis, menorrhagia) to life-threatening intracranial hemorrhage (<1% of cases but highest cause of ITP-related mortality). Fatigue — often disproportionate to platelet count — is reported by up to 70% of adult patients and significantly impairs physical functioning, work productivity, and emotional well-being. Anxiety about bleeding, treatment side effects (e.g., corticosteroid-induced insomnia or weight gain), and diagnostic uncertainty contribute substantially to reduced health-related quality of life (HRQoL). Patients frequently report limitations in daily activities, social engagement, and exercise tolerance. Chronic ITP (persisting >12 months) affects ~20–30% of adults and carries higher cumulative treatment burden and psychosocial morbidity. Early diagnosis requires careful exclusion of mimics (e.g., drug-induced thrombocytopenia, myelodysplastic syndromes, TTP) via comprehensive history, physical exam, complete blood count with peripheral smear, and often bone marrow evaluation in atypical cases. Management goals focus not solely on platelet count normalization but on preventing clinically significant bleeding while minimizing treatment toxicity and preserving long-term HRQoL.

Immune Thrombocytopenia (ITP) is an autoimmune disorder characterized by isolated thrombocytopenia (platelet count <100 × 10⁹/L) in the absence of other causes of low platelets, such as medication-induced thrombocytopenia, malignancy, or systemic lupus erythematosus. Diagnosis requires exclusion of secondary causes via thorough history, physical examination, complete blood count with peripheral blood smear, bone marrow aspiration (typically reserved for atypical presentations or patients over age 60), and serologic testing when clinically indicated. Management is risk-stratified—not all patients require immediate intervention. First-line therapy aims to rapidly increase platelet counts to prevent bleeding, while second-line strategies focus on sustained remission and minimizing long-term treatment toxicity.

Conservative management is foundational, especially in asymptomatic adults with platelet counts ≥30 × 10⁹/L and no mucocutaneous bleeding or comorbid risk factors (e.g., hypertension, anticoagulant use, or history of intracranial hemorrhage). Observation with serial platelet monitoring every 1–2 weeks initially, then monthly if stable, is appropriate. Patients are counseled to avoid nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, and other antiplatelet agents; limit alcohol intake; and refrain from contact sports or activities with high fall or trauma risk. Education on recognizing warning signs—such as petechiae, purpura, prolonged epistaxis, menorrhagia, or hematuria—is critical. In children, up to 80% experience spontaneous remission within 6–12 months; thus, watchful waiting is often preferred unless bleeding is moderate-to-severe.

Pharmacologic interventions are initiated based on bleeding severity, platelet count, and patient-specific risk. First-line therapy consists of corticosteroids: prednisone (0.5–2.0 mg/kg/day for 2–4 weeks, followed by a slow taper over 4–6 weeks) or high-dose dexamethasone (40 mg daily for 4 days, repeated after 2–4 weeks if needed). Intravenous immunoglobulin (IVIG) (1 g/kg/day × 1–2 days) or anti-RhD immunoglobulin (for Rh-positive, non-splenectomized patients) provides rapid but transient platelet elevation and is reserved for urgent situations (e.g., active bleeding, preoperative preparation, or platelet counts <20 × 10⁹/L with mucosal involvement). Second-line options include thrombopoietin receptor agonists (TPO-RAs)—eltrombopag (oral, 25–75 mg daily), avatrombopag (20–40 mg daily), and romiplostim (subcutaneous, weekly)—which stimulate megakaryocyte proliferation and platelet production. These agents demonstrate durable responses in ~60–80% of chronic ITP patients and are generally well tolerated, though liver enzyme monitoring (for eltrombopag) and bone marrow reticulin assessment (with long-term use) are recommended. Rituximab (375 mg/m² weekly × 4 doses) induces B-cell depletion and achieves response in ~40–60% of patients, though relapse rates are high (~50% at 2 years). Fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, is approved for refractory ITP and offers an oral, non-immunosuppressive alternative with modest efficacy (response rate ~18–43%). Emerging therapies under investigation include proteasome inhibitors (e.g., bortezomib), complement inhibitors (e.g., sutimlimab), and BAFF inhibitors.

Surgical treatment centers almost exclusively on splenectomy—the removal of the primary site of platelet destruction and autoantibody production. Laparoscopic splenectomy remains the gold-standard surgical intervention, offering >60% durable remission rates at 5 years. It is typically considered after failure of ≥2 lines of medical therapy, particularly in patients with chronic ITP (>12 months duration), good performance status, and absence of contraindications (e.g., portal hypertension or severe cardiovascular disease). Preoperative vaccination against encapsulated organisms (Streptococcus pneumoniae, Haemophilus influenzae type b, Neisseria meningitidis) is mandatory, ideally administered ≥2 weeks prior. While highly effective, splenectomy carries lifelong risks of overwhelming post-splenectomy infection (OPSI), venous thromboembolism, and pulmonary hypertension; therefore, shared decision-making emphasizing long-term surveillance and antibiotic prophylaxis is essential. Partial splenectomy and laparoscopic partial splenic embolization are investigational alternatives but lack robust evidence for routine use.

Treatment advantages in China reflect integrated clinical expertise, regulatory agility, and infrastructure scalability. The National Medical Products Administration (NMPA) has expedited approvals for novel ITP agents—including generic and biosimilar TPO-RAs—enhancing affordability and access across tier-1 to tier-3 hospitals. Leading academic centers (e.g., Peking University People’s Hospital, Ruijin Hospital Shanghai Jiao Tong University School of Medicine) maintain prospective ITP registries and conduct multicenter trials evaluating optimized corticosteroid tapering protocols and real-world TPO-RA sequencing. Traditional Chinese Medicine (TCM) adjuncts—such as Bushen Huoxue decoction—are rigorously studied in randomized controlled trials and show synergistic effects with conventional therapy in reducing steroid dependence and improving quality-of-life metrics, though they are never used as monotherapy for acute bleeding. Furthermore, China’s centralized electronic health record systems facilitate longitudinal platelet trend analysis and AI-assisted risk prediction models for hemorrhage, enabling proactive intervention. Telemedicine platforms now support rural follow-up, mitigating geographic disparities in hematologic care.

Recovery and long-term management emphasize multidisciplinary continuity. Patients achieving remission should undergo platelet monitoring every 3–6 months for at least 2 years, then annually if stable. Lifestyle counseling includes balanced nutrition rich in folate and vitamin B12, avoidance of herbal supplements with antiplatelet activity (e.g., ginkgo, garlic, ginger in excess), and annual influenza and pneumococcal vaccination (post-splenectomy patients require revaccination every 5 years). Psychosocial support is integral—chronic ITP correlates with elevated anxiety and depression scores—and referral to cognitive behavioral therapy or peer-support networks is encouraged. Women of childbearing potential require preconception counseling: most ITP therapies (except rituximab and fostamatinib) are compatible with pregnancy, and platelet counts often rise spontaneously during gestation. Finally, patients must carry medical identification indicating their diagnosis and treatment history—especially if splenectomized or on chronic immunosuppression—to guide emergency care. With contemporary risk-adapted strategies, over 85% of adults achieve treatment-free remission or stable low-risk disease, underscoring that ITP is increasingly a manageable chronic condition rather than a relentlessly progressive disorder.